Momenta Pharmaceuticals Inc Sample Contracts

November 8th, 2005 · Common Contracts · 452 similar
Momenta Pharmaceuticals IncRIGHTS AGREEMENT between MOMENTA PHARMACEUTICALS, INC. and AMERICAN STOCK TRANSFER & TRUST COMPANY as Rights Agent Dated as of November 7, 2005

RIGHTS AGREEMENT, dated as of November 7, 2005 (the “Agreement”), between Momenta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, as Rights Agent (the “Rights Agent”).

August 19th, 2020 · Common Contracts · 440 similar
Momenta Pharmaceuticals IncAGREEMENT AND PLAN OF MERGER by and among JOHNSON & JOHNSON, VIGOR SUB, INC. and MOMENTA PHARMACEUTICALS, INC. Dated as of August 19, 2020

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of August 19, 2020 by and among JOHNSON & JOHNSON, a New Jersey corporation (“Parent”), VIGOR SUB, INC., a Delaware corporation and a wholly owned Subsidiary of Parent (“Merger Sub”), and MOMENTA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”).

December 12th, 2019 · Common Contracts · 365 similar
Momenta Pharmaceuticals IncMomenta Pharmaceuticals, Inc. Common Stock, $0.0001 par value Underwriting Agreement

Momenta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 14,516,130 shares (the “Firm Shares”) and, at the election of the Underwriters, up to 2,177,419 additional shares (the “Optional Shares”) of Common Stock, par value $0.0001 (“Stock”) of the Company (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).

December 9th, 2010 · Common Contracts · 132 similar
Momenta Pharmaceuticals IncMOMENTA PHARMACEUTICALS, INC. 4,000,000 Shares Common Stock ($0.0001 par value per Share) UNDERWRITING AGREEMENT
August 8th, 2019 · Common Contracts · 57 similar
Momenta Pharmaceuticals IncMOMENTA PHARMACEUTICALS, INC. Common Stock ($0.0001 par value per share) AT- THE-MARKET EQUITY OFFERING SALES AGREEMENT

Momenta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or through Stifel, Nicolaus & Company, Incorporated (“Stifel Nicolaus”), as sales agent and/or principal (“Agent”), shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), having an aggregate offering price of up to $100,000,000 on the terms set forth in Section 2 of this At-the-Market Equity Offering Sales Agreement (the “Agreement”). The Company agrees that whenever it determines to sell Shares directly to the Agent as principal, it will enter into a separate agreement (each, a “Terms Agreement”) in substantially the form of Annex I hereto, relating to such sale in accordance with Section 3 of this Agreement.

March 15th, 2007 · Common Contracts · 32 similar
Momenta Pharmaceuticals IncMOMENTA PHARMACEUTICALS, INC. Executive Retention Agreement

THIS EXECUTIVE RETENTION AGREEMENT by and between Momenta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [ ] (the “Executive”) is effective as of the date of the last signature on the signature page attached hereto (the “Effective Date”).

May 10th, 2007 · Common Contracts · 17 similar
Momenta Pharmaceuticals IncConfidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. ASSET PURCHASE AGREEMENT dated April 20, 2007 among MOMENTA PHARMACEUTICALS, INC., PARIVID, LLC and S. RAGURAM

This Asset Purchase Agreement (the “Agreement”) is entered into as of April 20, 2007 by and among MOMENTA PHARMACEUTICALS, INC., a Delaware corporation (the “Buyer”), PARIVID, LLC, a Massachusetts limited liability company (the “Seller”) and S. RAGURAM, an individual residing at [**] (“Primary Member”).

December 12th, 2008 · Common Contracts · 16 similar
Momenta Pharmaceuticals IncSUBSCRIPTION AGREEMENT

The undersigned investor (the “Investor”) hereby confirms its agreement with Momenta Pharmaceuticals, Inc. (the “Company”) as follows:

September 23rd, 2009 · Common Contracts · 9 similar
Momenta Pharmaceuticals IncMOMENTA PHARMACEUTICALS, INC. (a Delaware corporation) 4,000,000 Shares of Common Stock UNDERWRITING AGREEMENT

Momenta Pharmaceuticals, Inc., a Delaware corporation (the “Company”) confirms its agreement with Leerink Swann LLC (“Leerink Swann”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Leerink Swann is acting as representative (in such capacity, the “Representative”), with respect to (i) the issue and sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Common Stock, par value $0.0001 per share, of the Company (“Common Stock”) set forth in said Schedule A, and (ii) the grant by the Company to the Underwriters, severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 600,000 additional shares of Common Stock to cover overallotments, if any. The aforesaid 4,000,000 shares of Common Stock (the “Initial Secur

March 11th, 2004 · Common Contracts · 7 similar
Momenta Pharmaceuticals IncEXHIBIT 10.22 RESTRICTED STOCK PURCHASE AGREEMENT (Peter Barton Hutt) This Restricted Stock Purchase Agreement dated as of June 13, 2001 (this "Agreement") is made by and between Mimeon, Inc., a Delaware corporation (the "Company"), and Peter Barton ...
December 12th, 2008 · Common Contracts · 7 similar
Momenta Pharmaceuticals IncMOMENTA PHARMACEUTICALS, INC. PLACEMENT AGENCY AGREEMENT
March 10th, 2008 · Common Contracts · 5 similar
Momenta Pharmaceuticals IncMOMENTA PHARMACEUTICALS, INC. Restricted Stock Agreement Granted Under 2004 Stock Incentive Plan

AGREEMENT made on December 14, 2007 between Momenta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and John Bishop (the “Participant”).

July 22nd, 2005 · Common Contracts · 5 similar
Momenta Pharmaceuticals Inc4,827,300 Shares MOMENTA PHARMACEUTICALS, INC. COMMON STOCK, PAR VALUE $0.0001 PER SHARE UNDERWRITING AGREEMENT

Momenta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) 4,827,300 shares (the “Firm Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”). The Company also proposes to issue and sell to the several Underwriters not more than an additional 724,095 shares (the “Additional Shares”) of Common Stock if and to the extent that you, as Managers of the offering, shall have determined to exercise, on behalf of the Underwriters, the right to purchase such shares of Common Stock granted to the Underwriters in Section 2 hereof. The Firm Shares and the Additional Shares are hereinafter collectively referred to as the “Shares.”

September 2nd, 2020 · Common Contracts · 4 similar
Momenta Pharmaceuticals IncEMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (the “Agreement”), made this 28th day of April 2008, is entered into by Momenta Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 675 West Kendall Street, Cambridge, Massachusetts (the “Company”), and Ian Fier, an individual residing at the address indicated below (the “Employee”).

September 2nd, 2020 · Common Contracts · 4 similar
Momenta Pharmaceuticals IncAugust 19, 2020

This letter agreement is in reference to the employment agreement between you and Momenta Pharmaceuticals, Inc. (the “Company”), dated as of April 28, 2008 (as amended through the date hereof, the “Employment Agreement”). As you know, Johnson & Johnson, a New Jersey corporation (“Parent”), Vigor Sub, Inc., a Delaware corporation and direct wholly owned subsidiary of Parent (“Merger Sub”), and the Company propose to enter into a merger agreement (the “Merger Agreement”) that will (subject to the satisfaction of the terms and conditions of the Merger Agreement) result in Merger Sub being merged with and into the Company as a result of the Merger (as defined in the Merger Agreement) and the Company surviving the Merger as a wholly owned subsidiary of Parent. As a condition to the willingness of Parent and Merger Sub to enter into the Merger Agreement, Parent has requested that you enter into this letter agreement setting forth certain modifications to your rights and obligations under the

May 3rd, 2019 · Common Contracts · 3 similar
Momenta Pharmaceuticals IncEXECUTIVE EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (the "Agreement"), effective as of May 9, 2016, is entered into by Momenta Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 675 West Kendall Street, Cambridge, Massachusetts (the "Company"), and Anthony Manning, an individual residing at 185 Hancock Street, Apt 2, Cambridge, MA 02139 (the "Employee").

February 22nd, 2019 · Common Contracts · 3 similar
Momenta Pharmaceuticals IncAGREEMENT AND GENERAL RELEASE

This Agreement and General Release (hereinafter “Agreement” or “Agreement and General Release”) is made by and between Momenta Pharmaceuticals, Inc. (“Momenta” or the “Company”) and Scott Storer (“Employee”). In order to resolve all matters relating to Employee’s employment, including but not limited to issues relating to the cessation of Employee’s employment, Momenta and Employee (collectively referred to as “the Parties”), voluntarily agree that:

May 11th, 2004 · Common Contracts · 2 similar
Momenta Pharmaceuticals IncFOR
November 8th, 2006 · Common Contracts · 2 similar
Momenta Pharmaceuticals IncNovartis Pharma AG AND Momenta Pharmaceuticals, Inc. INVESTOR RIGHTS AGREEMENT

THIS INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made as of July 25, 2006, by and between Novartis Pharma AG (the “Investor”), a corporation organized under the laws of Switzerland, with its principal place of business at Lichtstraße 35, CH 4058 Basel BS, and Momenta Pharmaceuticals, Inc. (the “Company”), a Delaware corporation with its principal place of business at 675 West Kendall Street, Cambridge, Massachusetts 02142.

November 8th, 2006 · Common Contracts · 2 similar
Momenta Pharmaceuticals IncNovartis Pharma AG AND Momenta Pharmaceuticals, Inc. STOCK PURCHASE AGREEMENT

THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of July 25, 2006, by and between Novartis Pharma AG (the “Investor”), a corporation organized under the laws of Switzerland, with its principal place of business at Lichtstraße 35, CH 4058 Basel BS, and Momenta Pharmaceuticals, Inc. (the “Company”), a Delaware corporation with its principal place of business at 675 West Kendall Street, Cambridge, Massachusetts 02142.

March 11th, 2004 · Common Contracts · 2 similar
Momenta Pharmaceuticals Inc1. PARTIES 68 Moulton Street Realty Trust, a (FILL IN) Massachusetts Trust with its mailing address of P.O. Box 95, Winchester, MA 01890. LESSOR, which expression shall include their heirs, successors, an assigns where the context so admits, does hereby ...
June 15th, 2004 · Common Contracts · 2 similar
Momenta Pharmaceuticals IncEXHIBIT 4.3 SECOND AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT This Second Amended and Restated Investors' Rights Agreement (this "Agreement") dated as of February 27, 2004 (this "Agreement") is made by and among Momenta Pharmaceuticals, Inc., a ...
November 8th, 2006 · Common Contracts · 2 similar
Momenta Pharmaceuticals IncMOMENTA PHARMACEUTICALS, INC. Restricted Stock Agreement Granted Under 2004 Stock Incentive Plan

AGREEMENT made on March 7, 2006 between Momenta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Ganesh Venkataraman (the “Participant”).

August 19th, 2020 · Common Contracts · 2 similar
Momenta Pharmaceuticals IncAugust 19, 2020 Young Kwon Chief Financial and Business Officer By email delivery Re: Retention Agreement Dear Dr. Kwon:

This letter agreement is in reference to the employment agreement between you and Momenta Pharmaceuticals, Inc. (the “Company”), dated as of July 29, 2011 (as amended through the date hereof, the “Employment Agreement”). As you know, Johnson & Johnson, a New Jersey corporation (“Parent”), Vigor Sub, Inc., a Delaware corporation and direct wholly owned subsidiary of Parent (“Merger Sub”), and the Company propose to enter into a merger agreement (the “Merger Agreement”) that will (subject to the satisfaction of the terms and conditions of the Merger Agreement) result in Merger Sub being merged with and into the Company as a result of the Merger (as defined in the Merger Agreement) and the Company surviving the Merger as a wholly owned subsidiary of Parent. As a condition to the willingness of Parent and Merger Sub to enter into the Merger Agreement, Parent has requested that you enter into this letter agreement setting forth certain modifications to your rights and obligations under the

March 11th, 2004 · Common Contracts · 2 similar
Momenta Pharmaceuticals IncEXHIBIT 10.19 CONSULTING AGREEMENT (Ram Sasisekharan) This Consulting Agreement dated as of August 16, 2001 (this "Agreement"), is made by and between Mimeon, Inc., a Delaware corporation (the "Company"), and Ram Sasisekharan ("Consultant"). WHEREAS, the ...
May 21st, 2004 · Common Contracts · 2 similar
Momenta Pharmaceuticals IncDEVELOPMENT AND PRODUCTION AGREEMENT FOR ACTIVE PHARMACEUTICAL INGREDIENT between
February 22nd, 2019 · Common Contracts · 2 similar
Momenta Pharmaceuticals IncEMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (the "Agreement"), made this 10th day of August, 2017, is entered into by Momenta Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 675 West Kendall Street, Cambridge, Massachusetts (the "Company"), and Alejandra Carvajal, an individual residing at 12 Wyman Street Waban, MA 02468 (the "Employee").

May 11th, 2004 · Common Contracts · 2 similar
Momenta Pharmaceuticals IncAND
February 3rd, 2017 · Common Contracts · 2 similar
Momenta Pharmaceuticals IncCOLLABORATION AGREEMENT BY AND BETWEEN MOMENTA PHARMACEUTICALS, INC. AND MYLAN IRELAND LIMITED, DATED AS OF JANUARY 8, 2016 Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have ...

This Collaboration Agreement (the “Agreement”), executed as of January 8, 2016 (the “Execution Date”), is made by and between Momenta Pharmaceuticals, Inc., a Delaware corporation (“Momenta”), with a principal place of business at 675 West Kendall Street, Cambridge, Massachusetts 02142, and Mylan Ireland Limited, a limited company organized under the laws of Ireland (“Mylan”), with a principal place of business at South Bank House, Barrow Street, 6th Floor, Dublin 4, Ireland. Momenta and Mylan may each be referred to individually as a “Party” or, collectively, the “Parties”.

May 9th, 2008
Momenta Pharmaceuticals IncSECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (the “Agreement”), made this 28th day of April 2008, is entered into by Momenta Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 675 West Kendall Street, Cambridge, Massachusetts (the “Company”), and Ganesh Venkataraman, an individual residing at the address indicated below (the “Employee”).

August 9th, 2018
Momenta Pharmaceuticals IncSIXTH AMENDMENT TO AND PARTIAL TERMINATION OF LEASE AGREEMENT

THIS SIXTH AMENDMENT TO AND PARTIAL TERMINATION OF LEASE AGREEMENT (this “Agreement”) is entered into as of this 2nd day of August, 2018 (“Execution Date”), by and between BMR-ROGERS STREET LLC, a Delaware limited liability company (“Landlord”) and MOMENTA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).

August 10th, 2005
Momenta Pharmaceuticals IncMOMENTA PHARMACEUTICALS, INC. 675 WEST KENDALL STREET T: 617.491.9700 F: 617.621.0431

Reference is made to the Consulting Agreement dated July 23, 2001 between Momenta Pharmaceuticals, Inc. (formerly Mimeon, Inc.) (“Momenta”), and you, as extended by the June 23, 2003 and July 2, 2004 letter agreements (collectively, the “Agreement”). Capitalized terms used herein and not otherwise defined shall have the meanings given such terms in the Agreement. The parties hereby amend the Agreement as follows:

May 11th, 2004
Momenta Pharmaceuticals IncEXECUTION COPY CONFIDENTIAL MATERIALS OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS. COLLABORATION AND LICENSE AGREEMENT
August 10th, 2020
Momenta Pharmaceuticals IncAgreement on Profit Based Settlement and Enoxaparin Transfer

This Agreement on Profit Based Settlement and Enoxaparin Transfer (the “Agreement”) is effective as of July 10, 2020 (the “Effective Date”) between Sandoz AG, a company organized under the laws of Switzerland, Sandoz Inc., a Colorado corporation (Sandoz AG and Sandoz Inc., collectively the “Sandoz Parties,” each individually a “Sandoz Party”) and Momenta Pharmaceuticals, Inc., a Delaware corporation (“Momenta,” collectively with the Sandoz Parties, the “Parties,” each individually a “Party.”).

September 20th, 2006
Momenta Pharmaceuticals IncAMENDMENT TO CONSULTING AGREEMENT

THIS AMENDMENT is made and entered into between MOMENTA PHARMACEUTICALS, INC., (formerly Mimeon, Inc.) (the “Company”) and Peter Barton Hutt, Esq. (“Consultant”) and amends the Consulting Agreement dated September 18, 2002, between the parties, as extended and amended by agreements effective as of September 29, 2003, October 4, 2004 and September 22, 2005 (collectively, the “Agreement”). Capitalized terms used herein and not otherwise defined shall have the meanings given such terms in the Agreement. The parties hereby amend the Agreement as follows: